06.25.26 -- What Reliance, Annex 1, And AI Mean For The Future Of GMP

Biologics manufacturing is evolving through smarter fill technologies, onshoring, advanced automation, and data driven processes that improve efficiency, reduce risk, and protect product value.

Explore trends in new molecular formats, which are one of the current drivers of renewed interest in fermentation technologies, along with some of their challenges. 

PCC boosts Protein A capture efficiency, cuts resin costs, increases productivity, and enables continuous downstream processing without sacrificing quality or compliance.

A platform-based upstream strategy increased monoclonal antibody titers fourfold, improving yield, efficiency, and scalability via optimized clones, process design, and rapid scale-up.

Learn how biopharmaceutical leaders address scalability, quality control, and regulatory challenges when manufacturing protein-based therapies at commercial scale.

Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

Learn how an approach with modular N-1 perfusion strategies shortens seed train timelines and reduces facility strain — enabling upstream processes that scale efficiently and reliably.

Choosing licensed vs. unlicensed cell lines impacts development speed, cost, flexibility, and long‑term control, making early strategic evaluation key to efficient biologics development.

In vitro bioequivalence can replace clinical studies for complex products when well designed. Clinically relevant, risk-based methods under realistic conditions show site-of-action equivalence.

Learn how data-driven developability screening and stress testing prioritize stable biologics early, cutting manufacturing risks for smoother clinical transitions.

A tailored LC–MS approach enables sensitive detection and tracking of monoclonal antibody variants, supporting deeper product characterization and better control of quality‑impacting changes.

Discover a practical roadmap for replacing animal tests with advanced molecular methods, as well as how regulatory updates and innovative technologies are shaping a sustainable future.

Understand how elite CDMO project management acts as a conductor—integrating molecule expertise, rigorous readiness, and disciplined GMP execution to drive successful programs.

Iwan Bertholjotti, director of commercial bioconjugate development, and Dr. Bernhard Stump, head of bioconjugate development, discuss complexity and uncertainty in the bioconjugates market.